CPA
CTKB icon

Capital Performance Advisors’s Cytek Biosciences CTKB Stock Holding History

Capital Performance Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed -$66 – 763
2024
Q3 		$66 Buy
+12
New +$68 ﹤0.01% 2764

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Performance Advisors's CTKB Position: Q4 2024 in Review

Capital Performance Advisors sold out of Cytek Biosciences (CTKB) in Q4 2024, closing a stake of 12 shares — an estimated $66 sold.

Capital Performance Advisors first reported a position in CTKB in Q3 2024 and held it in 1 quarter. The position peaked at $66 in Q3 2024. 152 funds tracked by Wall St. Rank hold CTKB as of Q4 2024.

  • Capital Performance Advisors reported no remaining Cytek Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 12 Cytek Biosciences shares in Q4 2024, an estimated $66.
  • Capital Performance Advisors first reported a position in Cytek Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Cytek Biosciences position peaked at $66 in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.